Facebook Intervention for Young Onset Melanoma Patients and Families.
The study has one primary and two secondary aims.
1)The primary aim (FDRs) is to examine the efficacy of the Young Melanoma Family
Facebook intervention versus the Healthy Lifestyle Facebook intervention on total cutaneous exam (primary outcome), skin self-exam frequency and comprehensiveness, and sun protection practices (secondary outcomes) of FDRs of young melanoma survivors.
2)A secondary aim (survivors) is to examine the efficacy of the Young Melanoma Family Facebook intervention on patients skin self-exam frequency and comprehensiveness and sun protection habits.
3)Another secondary aim is to examine the mechanisms of intervention efficacy.
- Rutgers Cancer Institute of New Jersey
Inclusion Criteria
- PATIENT: Diagnosed with stage 0-3 melanoma in the last 5 years
- PATIENT: Age at diagnosis 18-39 years
- PATIENT: Completed treatment at least 3 months previously
- PATIENT: Recruited from New Jersey or California State Cancer Registry or MD Anderson
Cancer Center
- PATIENT: Does not have a concurrent cancer diagnosis
- PATIENT: Able to speak and read English
- PATIENT: Access to computer, internet, and has a Facebook account
- PATIENT: At least one family member consents
- FDR: Current age 18-80 years
- FDR: Does not have a personal history of melanoma
- FDR: Able to speak and read English
- FDR: Access to computer, internet, and has a Facebook account
- FDR: Has only one FDR with melanoma (patient)
- FDR: Has not had a total cutaneous examination (TCE) in the past 3 years, has done
skin self-exam (SSE) fewer than three times in the past year, OR has a sun protection
habits average score less than or equal to 4 (?often?)
- FDR: Patient consents
Exclusion Criteria
- Physical Activity Readiness Questionnaire (Thomas, et. al., 1992): This 7-item scale
will be used to screen out individuals who will need to consult a physician for
medical clearance before engaging in physical activity. If a participant checks off
any of the items, the investigators will ask for a physician clearance before
consenting to study
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.